Correlation Of Haematological Parameters In Deep Vein Thrombosis

1981 ◽  
Author(s):  
D R Donaldson ◽  
M J Crow ◽  
G A Davies ◽  
S M Rajah ◽  
D A Watson
Keyword(s):  
Clot Lysis ◽  
Platelet Factor ◽  
Treatment Groups ◽  
Vein Thrombosis ◽  
Significant Difference ◽  
At Iii ◽  
Euglobulin Clot Lysis Time ◽  
Group A ◽  
Uptake Test ◽  
Group B

We have evaluated the response of certain haema to logical parameters in patients undergoing elective thoracotomy for pulmonary and oesophageal disease. These patients are part of a continuing DVT study in which prophylaxis is randomised to either i) Heparin 5000 iu 8 hourly s.c. (Group A) or ii) Heparin 2500 iu + Dihydroergotamine (DHE) 0.5 mg 8 hourly s.c. (Group B). Prophylaxis was commenced at the time of premedication and continued for 10 days. DVT was diagnosed by I125 Fibrinogen uptake test, with confirmatory venography if positive. The haema to logical parameters investigated were Antithrombin III (AT III), Euglobulin Clot Lysis Time (ECLT), plasma $-Thromboglobulin (β-Tg), platelet Factor 4 (PF4) and Heparin level. All investigations were performed pre-op. and day 6 post-op. (AT III and ECLT were also measured on day 3).A total of 50 patients have completed the study to date with 25 patients in each treatment group. Eleven patients have developed DVT - 5 in Group A and 6 in Group B. There was no significant difference between the pre-op. values in either group. The post-op. AT III values of patients developing DVT were lower than the two treatment groups. ECLT was significantly prolonged in the two treatment groups post-op. compared to the pre-op. values (p < 0.05 (A) and p < 0.01 (B)), but was not prolonged post-op. in the patients who developed DVT. Plasma β-Tg and PF4 were raised pre-op. with further increases post-op. in all groups. Plasma Heparin concentrations in Group B (0.122 iu/ml) were lower than for Group A (0.182 iu/ml) and the DVT group (0.176 iu/ml).These findings indicate that none of the haematological investigations were able to delineate ‘at risk’ patients. However the development of DVT was significantly correlated (p < 0.05) with the post-op. AT III and ECLT. The use of DHE in the dose cited above did not apparently inhibit the platelet release reaction

scholarly journals Graft and patient survival in portal vein thrombosis in living donor liver transplantation

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
A M Ramadan ◽  
N M Hytham ◽  
K K Mamdouh ◽  
A M Fathy
Keyword(s):  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Lower Survival Rate ◽  
Donor Liver Transplantation ◽  
Vein Thrombosis ◽  
Life Saving ◽  
Significant Difference ◽  
Group A ◽  
Group B ◽  
Stay Hospital

Abstract Background and Rational To date, only few studies have evaluated the benefits of anticoagulation in individuals with cirrhosis. An obvious goal of anticoagulation is PV recanalization: when cirrhotic individuals with PVT are treated with anticoagulation, complete recanalization has been described in 33–45% while partial PV recanalization is observed in 15–35% of cases. LDLT has emerged as the alternative life-saving treatment to DDLT. Over the past 2 decades, the number of LDLTs has steadily increased in many transplant centers, especially in Asia. The separation between occlusive and non-occlusive thrombosis is very important; in patients with partial PVT, post-transplant mortality outcomes are no different from non-PVT patients but it is significantly increased in patients with complete PVT. Patients and Methods This randomized prospective study will include 79 patients who will undergo LDLT in Ain Shams Specialized and Egypt Air hospitals, there are two groups of patients according to presence of portal vein thrombosis or not group A 39 patients of non PVT and group B 40 patient of PVT including different grades of PVT according Yerdel classification. Results In this study, there is no significant difference between groups regard age but Males were significantly associated with group B. In this study, there is no significant difference between groups regard CHILD and MELD scores and this findings. In our study there is no significantly difference between groups A and B regarding ICU stay, hospital stay and cell saver. In this study, comparisons of the PVT patients and controls showed no statistical significant differences regard HA thrombosis, post operative pulmonary embolism and biliary leak but PV rethrombosis is significantly associated with PVT patients, mortality sig associated with PVT patients. Conclusion The outcomes of patients with PVT who underwent LDLT are inferior to those without PVT. Patients with PVT has lower survival rate, higher postoperative PV rethrombosis.

HAEMOSTATIC PARAMETERS, ENDONEURIAL OXYGEN TENSION AND SURAL NERVE HISTOLOGY IN DIABETES MELLITUS

1987 ◽  
Author(s):  
I Ford ◽  
P G Newrick ◽  
R Malik ◽  
F E Preston ◽  
J D Ward ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Oxygen Tension ◽  
Sural Nerve ◽  
Clot Lysis ◽  
Diabetic Patients ◽  
Membrane Thickness ◽  
Basement Membrane Thickness ◽  
Significant Difference ◽  
Group A ◽  
Group B

We have examined coagulation parameters in 15 neuropathic (Group A) and 10 complication-free diabetic patients (Group B). Venesection and sample testing were performed under standard conditions. Group A underwent sural nerve biopsy and 14 also had measurements of endoneurial oxygen tension. Factor VIII related antigen was higher in Group A (l-617u/ml ± 0.67) compared to Group B (0.944u/ml ± 0.26); (mean ± SD; p<.0.05) perhaps suggesting endothelial cell damage, although this did not correlate with capillary basement membrane thickness or endothelial cell number nor with endoneurial oxygen levels. Platelets from Group A were more sensitive to arachidonate than those of Group B, showing aggregation thresholds in platelet rich plasma of 0.36 ± 0.17mM and 0.57 ± 0.9mM respectively compared with 0.65 ± 0.37mM in non-diabetic controls.Platelets from Group A subjects also produced more thromboxane B2 in response to arachidonate than Group B or normal controls (37.95 ± 27.5; 25.5 ± 13.0; 16.55 ± 15-5pmol/107 platelets). Blood fibrinolytic capacity measured by euglobulin clot lysis time, was diminished in NIDDs (post-occlusion ECLT 165.7 mins ± 116.0), compared to IDDs (55.5 ± 34.5) (p<0.05) due at least in part to excess of tissue plasminogen-activator inhibitor, although we found no significant difference in ECLT between Group A and Group B. Interaction between haemostatic and microvascular abnormalities in diabetes may contribute to the pathogenesis of diabetic neuropathy.

Exercise-Induced Platelet Activation in Myocardial Infarction Survivors with Normal Coronary Arteriogram

1984 ◽  
Vol 52 (03) ◽  
pp. 297-300 ◽  
Author(s):  
Ph Douste-Blazy ◽  
P Sié ◽  
B Boneu ◽  
J Marco ◽  
N Eche ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Platelet Activation ◽  
Plasma Levels ◽  
Healthy Subjects ◽  
Venous Blood ◽  
Peak Exercise ◽  
Platelet Factor ◽  
Significant Difference ◽  
Group A ◽  
Group B

SummaryPlatelet activation may participate in the pathophysiology of myocardial infarction occurring in patients with normal coronary arteriogram. We investigated this possibility in a series of 9 such patients (group A) during a standardized bicycle excercise test as myocardial infarction had occurred in all of them during or soon after strong physical exercise. Twelve patients with effort-induced angina and coronary atherosclerosis (group B) and eleven healthy subjects (group C) served as test groups. Peripheral venous blood was collected by separate venipuncture before, at peak exercise and during recovery. As a sensitive index of activation, the shape of the circulating platelets was examined with a phase contrast microscope after instantaneous fixation of the whole blood. The percentage of non strictly disc-shaped platelets with one or more thin pseudopods was determined. Simultaneously, the plasma levels of platelet factor 4 (PF4) and of beta-thromboglobulin (β-TG) were measured. At rest, there was no significant difference in the platelet morphology nor in the plasma levels of platelet specific proteins between the three groups. During exercise, a significant change in platelet shape occurred in group A and B patients and not in the healthy subjects. This platelet activation was not related to myocardial ischemia since it occurred to a similar extent in group B patients who developed electrocardiographic changes and in group A patients who did not. There was no detectable release of platelet proteins during exercise in any group.

scholarly journals Splinting in Carpal Tunnel Syndrome: The Optimal Duration

2020 ◽  
Vol 185 (11-12) ◽  
pp. e2049-e2054
Author(s):  
Michele A Gatheridge ◽  
Elsa A Sholty ◽  
Alexander Inman ◽  
Meghan Pattillo ◽  
Frank Mindrup ◽  
...  
Keyword(s):  
Carpal Tunnel Syndrome ◽  
Carpal Tunnel ◽  
The United States ◽  
Functional Improvement ◽  
Treatment Groups ◽  
Significant Difference ◽  
Group A ◽  
Tunnel Syndrome ◽  
Group B ◽  
Wrist Splint

Abstract Introduction The purpose of this study was to evaluate optimal neutral wrist splint duration in treatment-naive mild and mild to moderate carpal tunnel syndrome (CTS). Neutral wrist splinting is a conservative treatment for CTS; however, no clear guidelines exist for how long splinting should be prescribed for optimal outcomes. Materials and Methods In this prospective clinical trial subjects were assigned to wear a neutral wrist splint for 6 (group A) or 12 weeks (group B). Symptom and functional outcomes were assessed by questionnaire at baseline, 6 and 12 weeks. Median nerve sensory and motor latencies were recorded at baseline and 12 weeks. Pretreatment, midtreatment, and posttreatment measures were compared within and between treatment groups where applicable. This study was approved by the United States Air Force Academy institutional review board. Results A total of 30 subjects (37 hands) were randomized to 2 treatment groups. Mean symptom severity and median sensory peak latency significantly improved in both groups at 12 weeks, without a significant difference between groups. Mean functional severity significantly improved only in group A. Conclusion Neutral wrist splint for 6 weeks resulted in better clinical improvements in patients with untreated mild and mild to moderate CTS. There was no additional benefit in extending splinting 6 additional weeks. This is the first study to compare duration of wrist splint use beyond 8 weeks. A larger sample size is needed to identify the reason for lack of functional improvement in group B. Long-term follow-up of this cohort will be helpful to determine the natural history of initial wrist splint use.

scholarly journals Efficacy of Jatropha curcas Latex Cream in The Epithelialization Phase of Wound Healing in Mice Skin

2020 ◽  
Vol 151 ◽  
pp. 01038
Author(s):  
Muhammad N. Salim ◽  
Moma Silvia ◽  
Dwinna Aliza ◽  
Dian Masyitha ◽  
Cut D. Iskandar ◽  
...  
Keyword(s):  
Wound Healing ◽  
Quantitative Data ◽  
Statistical Test ◽  
Wound Therapy ◽  
Treatment Groups ◽  
Significant Difference ◽  
Group A ◽  
Group B ◽  
Incision Wound ◽  
Made In

The objective of the present research was to find out the efficacy of Jatropha latex cream in the epithelialization phase of wound healing in mice skin. A total of 9 male mice aged 2-3 months old and the bodyweight of 25-40 g were divided into three treatment groups. Group A was given basic cream, group B was given Jatropha latex cream (10%), and group C was given sulfadiazine. The 2 cm incision wound was made in the paravertebral area. Wound therapy was carried out twice a day for 7 days. All quantitative data were measured using ANOVA then followed by the Duncan test. The number of angiogenesis on A, B, and C was 4.67±1.20; 12.78±2.52; and 11.33±2.33, while a number of fibroblasts were 179.56±12.69; 90.56±8.23; and 99.11±7.04, respectively. The average deposition of collagen was 1.46±0.12; 1.89±0.10; and 1.74±0.06, respectively. The statistical test showed that the number of angiogenesis, fibroblast, and deposition of collagen on group B was significantly different (P<0.05) compared to group A and showed no significant difference compared to group C (P>0.05). In conclusion, Jatropha latex cream (10%) able to accelerate the epithelialization phase of wound healing in mice skin.

Systemic Fibrinolytic Activity and Inhibitor Levels During Treatment of Deep Vein Thrombosis with Urokinase and Streptokinase

1983 ◽  
Vol 50 (03) ◽  
pp. 664-668 ◽  
Author(s):  
W Theiss ◽  
F Asbeck ◽  
A Kriessmann ◽  
G Trübestein ◽  
K Knoch ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Fibrinolytic Activity ◽  
Clot Lysis ◽  
Treatment Groups ◽  
Vein Thrombosis ◽  
Lysis Time ◽  
Euglobulin Clot Lysis Time ◽  
Deep Vein ◽  
Dose Dependent ◽  
Urokinase Infusion

SummaryIn a prospective, randomized trial 33 patients with deep vein thrombosis were treated either with 2,200 or 1,100 IU/kg/h urokinase or with 100,000 IU/h streptokinase for at least 6 days. While streptokinase was given continuously, urokinase was administered intermittently (12 hr urokinase alternating with 12 hr heparin).Urokinase treatment resulted in a dose-dependent fibrinolytic state with shortening of the euglobulin clot lysis time, easily demonstrable amidolytic activity and moderate decrease of plasminogen. At the end of each urokinase-free interval the fibrinolytic activity had mostly faded, but was reproducibly elicited again by each new urokinase administration. Streptokinase immediately evoked the customary, intense fibrinolytic state, which progressively tapered off as plasminogen fell to 1% of its pretreatment concentration. In all treatment groups α-2-antiplasmin dropped to approximately 40% of its initial value during the first 12 hr with a further decrease to about 20% after 6 days, α-2-macroglo- bulin fell only moderately with either urokinase regimen, whereas it decreased progressively to 45% under streptokinase.While the fibrinolytic activity decreased under streptokinase over the 6-day infusion period, it appeared to increase with each successive urokinase infusion particularly with 1100 IU/kg/h. Thus the final euglobulin clot lysis times and the final fibrinogen concentrations were similar in all three treatment groups on the sixth day.

scholarly journals Efficacy of Oral Bilastine in Comparison with Levocetirizine in Allergic Rhinitis- A Randomised Clinical Study

2021 ◽  
Author(s):  
M Vanitha ◽  
K Sowmini ◽  
K Santha Sheela Kumari ◽  
Resu Neha Reddy
Keyword(s):  
Allergic Rhinitis ◽  
Immunoglobulin E ◽  
Statistical Significance ◽  
Post Treatment ◽  
Once Daily ◽  
Treatment Groups ◽  
Significant Difference ◽  
Group A ◽  
Group B ◽  
Antihistaminic Drugs

Introduction: Allergic rhinitis is a heterogeneous disorder characterised by major symptoms like sneezing, itching, nasal congestion and rhinorrhea. Because of bothersome side effects of first-generation antihistaminic drugs, second generation antihistaminic drugs have been used since few years. Recent studies have showed that novel drug Bilastine has been approved as an effective treatment in Allergic rhinitis. Aim: To evaluate Total Nasal Symptom Scores (TNSS), Serum Immunoglobulin E (IgE), Serum Absolute Eosinophil Count (AEC) in patients with allergic rhinitis, pre and post-treatment with Bilastine and Levocetirizine. Materials and Methods: A randomised, open-labelled, study was conducted between January 2020 to March 2020. Hundred patients with allergic rhinitis were enrolled into the study. They were randomised into two groups of which group A received tablet Bilastine 20 mg once daily for two weeks and group B received tablet Levocetirizine 5 mg once daily for two weeks. The results of TNSS, IgE, AEC and pre and post-treatment values were compared in both the treatment groups. Unpaired t-test was used as the test of significance between the two treatment groups. Results: The prevalence of allergic rhinitis in the study was 49% in males and 51% in females. The mean difference in pre and post-treatment in TNSS (group A=1.627, group B=1.143), serum IgE (A=33.118, B=49.653), serum AEC (A=28.00, B=27.245) showed no statistically significant difference between two groups (p-value >0.05). Conclusion: Bilastine and levocetirizine are equally efficacious. Though there is clinical significance in treatment of allergic rhinitis between the groups, there is no statistical significance which would prove Bilastine is clinically superior to Levocetirizine for the allergic rhinitis treatment.

scholarly journals Comparison of three interventional approaches to prevent ventilator-associated pneumonia in intensive care units (ICUs): A clinical trial study

2021 ◽  
Vol 2021 (2) ◽  
Author(s):  
Nader Zarinfar ◽  
Ehsanollah Ghaznavi-Rad ◽  
Behnam Mahmoodiyeh ◽  
Azita Reyhani
Keyword(s):  
Clinical Trial ◽  
Hand Washing ◽  
Ventilator Associated Pneumonia ◽  
Systematic Monitoring ◽  
Vein Thrombosis ◽  
Significant Difference ◽  
Group A ◽  
Group B ◽  
Prevention Methods ◽  
Airway Suctioning

Background: Ventilator-associated pneumonia (VAP) is an infectious pulmonary disease that develops after 48 hours of ventilation. To date, several methods have been proposed to reduce VAP occurrence, such as the VAP prevention bundle, which involves raising the head of the bed, reducing sedation, avoiding deep vein thrombosis, and preventing peptic ulcer in the gastrointestinal system. The purpose of this study was to evaluate the role of personnel in hand washing, case airway suctioning, and systematic monitoring in the prevention of VAP. Methods: In the current clinical trial, 129 patients hospitalized and intubated at Vali-e-Asr Hospital ICU in Arak, Iran, were included in the study and randomized to one of the three VAP prevention methods: group A, VAP prevention bundle measures; group B, group A measures plus washing of patients’ mouth with 0.12% chlorhexidine and suction of secretion every six hours; and finally group C, group B measures plus 72-hour suction package. Demographic information, VAP diagnosis, and outcome of each patient were recorded in the special checklist. Results: The age of the patients ranged from 18 years to 93 years with a mean of 54.6 ± 21.8 years. There was no significant difference in age, sex, Clinical Pulmonary Infection Score (CPIS), and Glasgow Coma Scale (GCS) between the three groups. However, there is a significant relationship between chest X-ray (CXR) index and pneumonia in the three groups (p < 0.05). The prevalence of pneumonia is generally seen to be higher in patients who were local, diffuse, or patchy than those who had no infiltration (p < 0.05). Conclusion: This study showed that the application of VAP prevention bundle measures, mouthwash with chlorhexidine, personnel hand washing, airway suctioning, and systematic monitoring is an efficient approach to the prevention of VAP in ICUs.

scholarly journals Adjunctive Corticosteroids for COVID-19: A Retrospective Cohort Study

2020 ◽  
Author(s):  
Say Tat Ooi ◽  
Purnima Parthasarathy ◽  
Yi Lin ◽  
Valliammai Nallakaruppan ◽  
Shereen Ng ◽  
...  
Keyword(s):  
Lower Risk ◽  
Retrospective Cohort ◽  
Treatment Initiation ◽  
Cox Regression ◽  
Clinical Progression ◽  
Cox Regression Analysis ◽  
Treatment Groups ◽  
Significant Difference ◽  
Group A ◽  
Group B

Background: Coronavirus disease 2019 (COVID-19) is associated with severe pneumonia, respiratory failure and death. We aim to evaluate the efficacy of adjunctive corticosteroids in the management of COVID-19. Methods: This is a retrospective cohort study of hospitalized adults (≥18 years) who were diagnosed with COVID-19 and were given treatment. Treatment included hydroxycholoroquine and lopinavir-ritonavir. Corticosteroids were included as adjunctive therapy in mid-April, 2020. We compared composite outcomes of clinical progression and invasive mechanical ventilation (MV) or death between group that received treatment only (Group A) versus group that received adjunctive corticosteroids (Group B). Entropy balancing was used to generate stabilized weight for covariates between treatment groups. Unweighted Kaplan-Meir curves, weighted and adjusted Cox regression analysis were used to estimate effect of adjunctive corticosteroids on composite outcomes. Subgroup analysis was performed on those with pneumonia. Results: Of 1046 patients with COVID-19, 57 received treatment alone (Group A) and 35 received adjunctive corticosteroids in addition to treatment (Group B). Median day of illness at treatment initiation was 5 day. There were 44 patients with pneumonia; 68.9% of them were not requiring supplemental oxygen at treatment initiation. Overall, 17 (18.5%) of 92 patients had clinical progression including 13 (22.8%) of 57 patients in Group A versus 4 (11.4%) of 35 patients in Group B (p=0.172). Unweighted Kaplan-Meier estimates showed no significant difference in the proportion of patients who had clinical progression or invasive MV or death between the 2 treatment groups. However in those with pneumonia, there were lower proportions of patients in Group B with clinical progression (11.1% , 95% CI 0.0 - 22.2 versus 58.8%, 95% CI 27.3 - 76.7, log rank p<0.001 ); and invasive MV or death (11.3%, 95% CI 0.0 - 22.5 versus 41.2%, 95% CI 12.4. - 60.5, log rank p=0.016). In weighted and adjusted cox regression analysis, patients in Group B were less likely to have clinical progression, (adjusted HR [aHR] 0.08, 95% CI 0.01-0.99, p=0.049) but there was no statistical significant difference in risk of requiring invasive MV or death (aHR 0.22, 95%CI 0.02 - 2.54, p=0.22). In subgroup with pneumonia, patients in Group B were significantly at lower risk of clinical progression (aHR 0.15, 95% CI 0.06 - 0.39, p<0.001) and requiring invasive MV compared to Group A (aHR 0.30, 0.10-0.87, p=0.029). Conclusions: Use of adjunctive corticosteroids is associated with lower risk of clinical progression and invasive MV or death, especially in those with pneumonia. Concurrent use of antivirals and corticosteroids should be considered in the management of COVID-19 related pneumonia.

scholarly journals Improving Effect of Promoting Cerebral Circulation on Patients with Senile Dementia

2020 ◽  
Vol 1 (3) ◽  
Author(s):  
Mingmin Deng
Keyword(s):  
Cerebral Circulation ◽  
Senile Dementia ◽  
Effective Rate ◽  
Therapeutic Effects ◽  
Treatment Groups ◽  
Significant Difference ◽  
Hamd Score ◽  
Group A ◽  
Grouping Method ◽  
Group B

Purpose — To explore the improving effect of promoting cerebral circulation on patients with senile dementia. Methods — 96 patients with senile dementia admitted from January 2018 to December 2019 were selected and divided into A (conventional treatment) and B (conventional + promoting cerebral circulation treatment) groups, 48 cases in each group, according to the computerized flow grouping method. The clinical therapeutic effects of the two groups were compared and analyzed. Results — ① Compared with Group A, the total effective rate of Group B was higher (95.83%>83.33%) (c2=4.019, P=0.045); ② Before treatment, there was no significant difference between groups (P>0.05). After treatment, compared with Group A, Group B had higher MMSE score, lower ADAS-cog score, HAMD score and ADL score (P<0.05); ③ During the clinical treatment of the two groups, no obvious adverse reactions were seen. Conclusion — The treatment of promoting cerebral circulation in patients with senile dementia can not only effectively improve the symptoms of dementia, but also improve the ability of daily living. This therapy is safe and reliable, and is worthy of clinical promotion and use.

Sign in / Sign up

Export Citation Format

Share Document